Prot #RD.03.SPR.114322: A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receiv

  • Silverberg, Jonathan I (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/15/1711/15/20

Funding

  • Parexel (Prot #RD.03.SPR.114322)
  • Galderma Research & Development, SNC (Prot #RD.03.SPR.114322)